A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2019
Price : $35 *
At a glance
- Drugs INCB 62079 (Primary)
- Indications Cholangiocarcinoma; Liver cancer; Nasopharyngeal cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Proof of concept
- Sponsors Incyte Corporation
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2017 Status changed from not yet recruiting to recruiting.
- 05 May 2017 Status changed from planning to not yet recruiting.